Cryptocurrency & Fintech - Solana 上 USDC 兑换成阿联酋商业银行账户法币的最佳场外交易价格为 15 个基点，即 0.15% [1] - @sphere 提供 USDC 到阿联酋商业银行账户的链下交易服务，一个工作日内完成 [1]

General Sentiment - The author expresses frustration with discussions about OTC (Over-the-Counter) topics [1] - The author implies a lack of common sense in OTC discussions [1]

Newly created wallet 0x3dF3 just bought another 32,640 $ETH($122.18M) through OTC, for a total of 43,787 $ETH($163M) in the past 4 days.https://t.co/rZZdoV7NJi https://t.co/M8GrYeNiSm ...

Ethereum Foundation Activities - The Ethereum Foundation (EF) completed a 10,000 ETH sale via OTC [1] - The average price of the ETH sale was $2,572.37 [1] - SharpLink Gaming was the OTC counterparty for this sale [1]

Financial Transactions - SharpLink Gaming 通过场外交易 (OTC) 收购了 1,989 ETH，价值 482 万美元 [1]

Group 1 - The pharmaceutical and healthcare sector has experienced a significant rebound, with the Wind Innovation Drug Index showing a year-to-date increase of over 20% and the Hong Kong innovation drug sector leading the market with nearly a 50% rise [1] - The Hong Kong pharmaceutical ETF has become a market focus, with the largest innovation drug ETF reaching a size of 13.59 billion and a net inflow of 230 million over the past five trading days, reflecting a growth of over 6% in the last month [1] - Key stocks in the ETF include WuXi Biologics and BeiGene, which have a research and development expenditure ratio exceeding 15%, with net profit growth and overseas expansion capabilities being the core logic for investment [1] Group 2 - The medical theme fund managed by the China-Europe Medical Fund has stabilized at 40 billion, focusing on innovative drugs, medical devices, and domestic substitution in key industry chains [2] - For instance, Hengrui Medicine is projected to achieve a revenue growth of 22.63% and a net profit growth of 47.28% in 2024, with 17 self-developed innovative drugs contributing nearly 50% of sales revenue [2] - Recent policy changes in China, including the establishment of a drug pricing mechanism and the inclusion of high-value innovative drugs in pilot programs, are expected to support the recovery of the sector [2] Group 3 - The current policy environment emphasizes innovation, contrasting with previous industry shocks caused by generic drug procurement, leading to a faster valuation recovery for companies with sustained R&D capabilities [3] - The China-Europe Medical Fund's report indicates a continued focus on innovative drugs, medical devices, and consumer healthcare, with optimism about breakthroughs in innovative drugs and the recovery of consumer healthcare [3] - The pharmaceutical and healthcare sector is anticipated to benefit from favorable development opportunities as more innovative drugs are successfully launched and the market expands [3]